FATE
Fate Therapeutics, Inc. Healthcare Biotechnology
5/12
Innovation Score
Red Flags (1)
SBC_HIGH (424% of revenue)
Patent Activity
3/3
18 patents found
ALIAS_FUZZY
Cash Runway
1/3
20 months of cash remaining based on current burn rate.
Cash on hand: $174.8M
Cash on hand: $174.8M
Revenue Trajectory
0/3
Revenue: $6.3M
YoY Growth: -20.3%
YoY Growth: -20.3%
Management Quality
1/3
Insider ownership: 12.6%
SBC/Revenue: 424.5%
No reverse splits detected
SBC/Revenue: 424.5%
No reverse splits detected
Key Metrics
Market Cap
$244.8M
Revenue
$6.3M
Revenue Growth (YoY)
-20.3%
Cash on Hand
$174.8M
Cash Runway
20 months
Shares Outstanding
116.6M
Insider Ownership
12.6%
SBC / Revenue
424.5%
Sector / Industry
Healthcare / Biotechnology
Patents (18)
Match type: ALIAS_FUZZY
- Combining iPSC derived effector cell types for immunotherapy use
- Vial rack
- Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
- Compositions and methods for immune cell modulation in adoptive immunotherapies
- Compositions and methods for immune cell modulation in adoptive immunotherapies
7-Step Risk Assessment
How FATE maps to our micro cap methodology:
- Innovation Signal 18 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 20 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory -20.3% YoY growth on $6.3M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 12.6% of shares. SBC is 424.5% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $244.8M company.
Financial Detail
Free Cash Flow
$-50.1M
FCF Yield
-20.4%
Return on Equity
-55.5%
Debt / Equity
42.7%
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
-2540.4%
Price / Book
1.36
Current Ratio
5.85
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Quality Flags
Low Debt
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-06-27